Phase 1 Subcutaneous Clinical Trials
7 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–7 of 7 trials
Recruiting
Phase 1Phase 2
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
Aggressive NK-cell LeukemiaLGLL - Large Granular Lymphocytic LeukemiaPrimary Cutaneous Gamma-Delta T-Cell Lymphoma+10 more
Dren Bio200 enrolled37 locationsNCT05475925
Not Yet Recruiting
Phase 1
Phase 1 Study of CLIP-100 in Healthy Adults
Localized Subcutaneous Fat (Abdominal)
Amalfi Bio, Inc25 enrolled1 locationACTRN12626000483358
Recruiting
Phase 1
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
Advanced Solid TumorMetastatic Solid TumorNon-small Cell Lung Cancer+6 more
Ankyra Therapeutics, Inc97 enrolled5 locationsNCT06171750
Active
Phase 1
A Phase I study of increasing doses of T3011 in patients with advanced cancer
Any malignancy with cutaneous and/or subcutaneous tumours
Theravir Pty Ltd24 enrolled3 locationsACTRN12620000008921
Completed
Phase 1
A Phase 1 Study to Evaluate the Safety of CBL-514 Injection on Convexity or Fullness of Abdominal Subcutaneous Fat in Healthy Volunteers
Healthy to overweight subjects with undesirable subcutaneous fat thickness in belly
Caliway Biopharmaceuticals Australia Pty Ltd40 enrolled1 locationACTRN12618000868280
Completed
Phase 1
Phase I Dose-Escalation Extension Study to Determine the Safety and Tolerability of Intratumoural Injection(s) of EBC-46
Cutaneous, subcutaneous, head and neck*, or nodal tumours
*except for pharyngeal, laryngeal and tongue base tumours and those tumours in the anterior neck (from posterior border of sternocleidomastoid on each side)
QBiotics Limited15 enrolled5 locationsACTRN12614001207606
Completed
Phase 1
Phase I Dose-Escalation Study to Determine the Safety and Tolerability of an Intratumoural Injection of EBC-46
Cutaneous, subcutaneous, head and neck*, or nodal tumours
*except for pharyngeal, laryngeal and tongue base tumours and those tumours in the anterior neck (from posterior border of sternocleidomastoid on each side)
QBiotics Limited15 enrolled5 locationsACTRN12614000685617